May 3, 2007
Maxygen to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference
Redwood City, Calif., May 3, 2007 – Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monte Carlo, Monaco, on Tuesday, May 15, 2007 at 11:10 a.m. Central Europe Time (5:10 a.m. Eastern Time). Russell Howard, Maxygen’s chief executive officer, will present. A live webcast of the presentation can be accessed at http://www.wsw.com/webcast/rrshq11/maxy or by visiting the investor relations section of Maxygen’s website at www.maxygen.com. The webcast will be archived for 90 days.
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Products developed by Maxygen now in clinical trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia. Maxygen’s approach may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. www.maxygen.com
Return to News